Protagonist Therapeutics said its cash balance stood at roughly $850 million at the end of the second quarter of 2024. The company added $275 million from a milestone and opt‑out fee tied to its MIMRYLO (rusfertide) program, pushing pro‑forma cash above the $1 billion mark.
Alongside the cash update, Protagonist unveiled a $300 million share‑repurchase plan, expanding its capital‑return strategy. The firm’s market capitalization was reported at $9.36 billion, with a current ratio of 21.71, a 151 percent total‑share return over the past year and a 66 percent gain year‑to‑date. Revenue has risen 35 percent over the last twelve months, while the price‑to‑earnings multiple sits at 118.78.
At the 12th Annual Cantor Fitzgerald Global Healthcare Conference, President and CEO Dinesh Patel highlighted the launch of icotrokinra, an oral IL‑23 antagonist developed with Johnson & Johnson. The drug targets psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease, and is taken with water or coffee, avoiding solid food for 30 minutes. Phase‑2 data in ulcerative colitis showed a 30 percent clinical remission rate, prompting J&J to move directly into Phase‑3 studies for ulcerative colitis and a combined Phase‑2b/3 trial in Crohn’s disease.
Protagonist also discussed its partnership with Takeda on MIMRYLO, a hepcidin mimetic approved for polycythemia vera. The FDA label includes a claim for fatigue improvement, a first for the indication. Takeda had previously forecasted peak sales of $1 billion to $2 billion for the product before Phase‑3 data were available.
The pipeline includes PN‑881, an oral IL‑17 candidate slated for a Phase‑2b study in psoriasis and later hidradenitis suppurativa, and an oral triple‑agonist aimed at obesity and metabolic disease that combines GLP‑1, GIP and glucagon activity. Pre‑clinical data suggest potency comparable to retatrutide, with a GLP‑1/GIP‑only version under development as a risk‑mitigation option.
Patel concluded that the company’s broad label for MIMRYLO and its expanding oral‑peptide platform position Protagonist to “revolutionize the landscape of chronic indications.”
